Conversion from cilostazol to OPC‐13015 linked to mitigation of cognitive impairment
Open Access
- 1 January 2021
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 7 (1) , e12182
Abstract
Introduction: Cilostazol may be a novel therapeutic agent for Alzheimer's disease. Its metabolite, OPC‐13015, has a stronger inhibitory effect on type 3 phosphodiesterase than cilostazol. Methods: We prospectively enrolled patients with mild cognitive impairment to whom cilostazol was newly prescribed. Patients underwent the Montreal Cognitive Assessment (MoCA) twice, at a 6‐month interval. Plasma cilostazol, OPC‐13015, OPC‐13213, and OPC‐13217 concentrations were determined using liquid chromatography‐tandem mass spectrometry. Results: MoCA score changes from baseline to the 6‐month visit were positively correlated with ratios of OPC‐13015 to cilostazol and total metabolites ( n = 19, P = .005). Patients with higher ratios of OPC‐13015 (≥0.18, median value; n = 10) had significantly higher MoCA scores ( P = .036) than patients with lower ratios (the ratio n = 9). The absolute value of OPC‐13015 concentration in blood was also higher in patients with preserved cognitive function ( P = .033). Discussion: Blood OPC‐13015 levels may be a predictive biomarker of cilostazol treatment for Alzheimer's disease.Keywords
Funding Information
- Japan Agency for Medical Research and Development (20ek0210120h0002)
This publication has 38 references indexed in Scilit:
- Quantifying factors for the success of stratified medicineNature Reviews Drug Discovery, 2011
- Decreased Clearance of CNS β-Amyloid in Alzheimer’s DiseaseScience, 2010
- Improving Interrater Agreement About Brain MicrobleedsStroke, 2009
- Amyloid-β Peptide Remnants in AN-1792-Immunized Alzheimer's Disease PatientsThe American Journal of Pathology, 2006
- The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive ImpairmentJournal of the American Geriatrics Society, 2005
- Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case reportNature Medicine, 2003
- Cilostazol (Pletal®): A Dual Inhibitor of Cyclic Nucleotide Phosphodiesterase Type 3 and Adenosine UptakeCardiovascular Drug Reviews, 2001
- The Clinical Dementia Rating (CDR)Neurology, 1993
- Mild senile dementia of the Alzheimer type. 4. Evaluation of interventionAnnals of Neurology, 1992
- Effects of Cilostazol, a Selective cAMP Phosphodiesterase Inhibitor on the Contraction of Vascular Smooth MusclePharmacology, 1988